PharmDecks

Menu
Login
Sign Up

Stop These 5 Antibiotic Mistakes Before They Spread Resistance

Getting the basics right with beta-lactams saves patients from avoidable harm and keeps our antibiotics useful. These are the errors that crop up again and again in student prescribing, plus practical ways to fix them.

 

1) Labelling “penicillin allergy” without a proper history

The error: Treating any past rash or vague reaction as a true IgE-mediated allergy, then avoiding all beta-lactams forever.

Why it matters: Most recorded “penicillin allergies” aren’t true allergies. Cross-reactivity with cephalosporins is far lower than the old 10% myth, and largely related to similar side chains. Over-avoiding beta-lactams pushes people onto broader agents with more harm. (PubMed)

Fix it:

  • Take a structured history: drug, timing, symptoms, treatment sought, and time since reaction. Immediate anaphylaxis or angio-oedema is different from a delayed benign rash.

  • If the history suggests low risk or a non-allergic reaction, many cephalosporins can still be used; seek senior advice and consider side-chain differences.

  • For any severe immediate reaction, avoid related beta-lactams and refer for allergy assessment and delabelling where appropriate. (BSACI)

 

2) Using amoxicillin for sore throat, or missing EBV-associated rashes

The error: Reaching for amoxicillin for acute sore throat or suspected tonsillitis.
Why it matters: NICE recommends phenoxymethylpenicillin as first-line when antibiotics are indicated; many sore throats need no antibiotic at all. Amoxicillin during infectious mononucleosis (EBV) frequently causes a marked generalised rash, confusing future allergy records. (NICE) (PubMed)

Fix it:

  • For adults, if antibiotics are needed, prescribe phenoxymethylpenicillin 500 mg QID or 1 g BD for 5–10 days per NICE NG84.

  • Avoid amoxicillin when EBV is suspected (marked fatigue, lymphadenopathy, splenomegaly). Document clearly if a rash occurs during EBV to prevent a spurious “penicillin allergy” label. (NICE) (NEJM)

 

3) Going broad when narrow will do (and not reviewing at 48–72 hours)

The error: Starting co-amoxiclav or a cephalosporin “just in case,” then forgetting to review.
Why it matters: Broad-spectrum agents like co-amoxiclav and many cephalosporins carry higher C. difficile risk. Good stewardship requires early review to stop, switch to oral, or narrow the spectrum once results and clinical response are available. (NICE) (NICE) (GOV.UK)

Fix it:

  • Start smart, then focus: document indication, dose, route and review at 48–72 hours for IV-to-oral switch or de-escalation.

  • Prefer narrow-spectrum penicillins (e.g., flucloxacillin for MSSA skin infection; phenoxymethylpenicillin for streptococcal pharyngitis) when they cover the likely pathogen. (GOV.UK)

 

4) Forgetting renal function and practical dosing limits

The error: Copy-pasting standard doses without checking eGFR or dialysis status.
Why it matters: Many penicillins and cephalosporins are renally cleared. In moderate to severe impairment, dose reductions or extended intervals are needed to avoid accumulation and neurotoxicity, while maintaining efficacy. Cefalexin is a classic example with specific maximum daily doses that fall as renal function declines. (BNF) (NICE)

Fix it:

  • Check eGFR/CrCl before prescribing and look up renal dosing in the BNF or your local renal-dosing guide.

  • Be alert to formulation constraints: some oral products can’t deliver tiny intervals or awkward strengths; choose a regimen patients can actually take.

  • Reassess dosing if renal function changes during admission. (BNF)

 

5) Missing high-impact interactions and safety warnings

The error: Prescribing “safe” penicillins or cephalosporins without checking interactions or cumulative risks.
Why it matters:

  • Methotrexate: penicillins can reduce renal clearance and raise methotrexate levels — toxicity can be serious. (SPS – Specialist Pharmacy Service)

  • Warfarin: antibiotics may increase INR; cephalosporins such as ceftriaxone have shown larger INR rises in some settings — monitor closely. (NICE)

  • Flucloxacillin: linked to cholestatic liver injury, particularly with prolonged courses or in older adults. Monitor and keep durations tight. (PubMed)

Fix it:

  • Always run an interaction check and plan INR or methotrexate monitoring where relevant; arrange follow-up bloods if treatment continues beyond a few days.

  • Keep flucloxacillin courses short where appropriate; if therapy is prolonged, watch LFTs and counsel on jaundice/itching. (PubMed)

 

Quick pre-prescribing checklist

  • Is an antibiotic indicated at all? Follow NICE; many URTIs are self-limiting. (NICE)

  • Have you clarified allergy history and recorded exact symptoms and timing? Consider side-chain issues before blanket avoidance. (PubMed)

  • Can you go narrower? Avoid co-amoxiclav/cephalosporins unless clearly indicated; plan a 48–72-hour review. (GOV.UK)

  • Have you checked renal function and practical dosing? Dose-adjust and choose an achievable regimen. (BNF)

  • Any interactions or safety monitoring needed? Especially methotrexate or warfarin. (SPS – Specialist Pharmacy Service)

 

Take-home message

Most errors come from reflex habits: writing “penicillin allergy,” grabbing a broad agent, or skipping a quick renal/interaction check. If you build a routine, confirm the indication, verify the allergy, choose narrow-spectrum first, check kidneys, check interactions, and review at 48–72 hours — you’ll avoid the common pitfalls and prescribe penicillins and cephalosporins safely and effectively. (GOV.UK)

 

If you’d like to dive deeper into how these mechanisms tie into prescribing decisions, check out the PharmDecks Infectious Diseases & Antimicrobials module.